Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares, NIS 1.80 par value per share
-
Shares outstanding
-
5,591,387
-
Total 13F shares
-
44,767
-
Share change
-
+39,167
-
Total reported value
-
$142,806
-
Price per share
-
$3.19
-
Number of holders
-
11
-
Value change
-
+$124,943
-
Number of buys
-
4
-
Number of sells
-
1
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q4 2024
As of 31 Dec 2024,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,767 shares.
The largest 10 holders included
Schonfeld Strategic Advisors LLC, MORGAN STANLEY, UBS Group AG, Tower Research Capital LLC (TRC), WELLS FARGO & COMPANY/MN, SBI Securities Co., Ltd., Federation des caisses Desjardins du Quebec, OSAIC HOLDINGS, INC., Allworth Financial LP, and Dogwood Wealth Management LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.